All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Ghayas Issa, MD Anderson Cancer Centre, Houston, US. We asked, What do the data tell us about menin inhibition in relapsed/refractory acute myeloid leukemia (AML)?
Menin inhibition in relapsed/refractory AML: what do the data tell us?
Issa explains the mechanism of action of menin inhibitors, then goes on to describe the positive findings from phase I studies of ziftomenib and revumenib in relapsed/refractory AML, including for patients with NPM1 mutations and KMT2A rearrangements. Issa also discusses data for a subset of patients treated with revumenib who underwent hematopoietic stem cell transplantation and outlines plans for combination studies of menin inhibitors with other agents.
Adding ex vivo chemosensitivity assay to mutational profiling improves the ability to predict the outcome of patients with AML
Adding ex vivo chemosensitivity assay to mutational profiling improves the ability to predict the outcome of patients with...
MRD monitoring before and after allo-HSCT predicts outcomes
The presence of measurable (minimal) residual disease (MRD) after induction chemotherapy is a strong and independent prognostic marker of increased risk of relapse and shorter survival in...
Subscribe to get the best content related to AML delivered to your inbox